Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization | Zendy

William R. Hiatt | Zendy; Marc P. Bonaca | Zendy; Manesh R. Patel | Zendy; Mark R. Nehler | Zendy; E. Sebastian Debus | Zendy; Sonia S. Anand | Zendy; Warren H. Capell | Zendy; Taylor Brackin | Zendy; Nicole Jaeger | Zendy; Connie N. Hess | Zendy; Ákos F. Pap | Zendy; Scott D. Berkowitz | Zendy; Eva Muehlhofer | Zendy; Lloyd Haskell | Zendy; David Brasil | Zendy; Juraj Maďarič | Zendy; Henrik Sillesen | Zendy; David Szalay | Zendy; Rupert Bauersachs | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization

Author(s) -

William R. Hiatt,

Marc P. Bonaca,

Manesh R. Patel,

Mark R. Nehler,

E. Sebastian Debus,

Sonia S. Anand,

Warren H. Capell,

Taylor Brackin,

Nicole Jaeger,

Connie N. Hess,

Ákos F. Pap,

Scott D. Berkowitz,

Eva Muehlhofer,

Lloyd Haskell,

David Brasil,

Juraj Maďarič,

Henrik Sillesen,

David Szalay,

Rupert Bauersachs

Publication year - 2020

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.050465

Subject(s) - medicine , rivaroxaban , clopidogrel , aspirin , revascularization , myocardial infarction , stroke (engine) , cardiology , hazard ratio , clinical endpoint , timi , surgery , anesthesia , randomized controlled trial , thrombolysis , warfarin , atrial fibrillation , confidence interval , mechanical engineering , engineering

The VOYAGER PAD trial (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) demonstrated superiority of rivaroxaban plus aspirin versus aspirin to reduce major cardiac and ischemic limb events after lower extremity revascularization. Clopidogrel is commonly used as a short-term adjunct to aspirin after endovascular revascularization. Whether clopidogrel modifies the efficacy and safety of rivaroxaban has not been described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research